What is HC Wainwright’s Estimate for SGMT FY2030 Earnings?

Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Research analysts at HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for Sagimet Biosciences in a report released on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $2.09 per share for the year, down from their previous estimate of $2.28. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.25) per share.

Several other equities analysts have also recently weighed in on SGMT. Wells Fargo & Company set a $27.00 target price on shares of Sagimet Biosciences in a research note on Friday. Wall Street Zen downgraded shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Guggenheim upped their price target on shares of Sagimet Biosciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. Finally, Oppenheimer increased their price target on shares of Sagimet Biosciences from $33.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.07.

Check Out Our Latest Research Report on Sagimet Biosciences

Sagimet Biosciences Stock Down 2.8%

Shares of Sagimet Biosciences stock opened at $9.85 on Monday. Sagimet Biosciences has a 12-month low of $4.50 and a 12-month high of $11.45. The stock has a market cap of $612.28 million, a P/E ratio of -8.28 and a beta of 3.43. The business’s 50 day moving average is $9.85 and its 200-day moving average is $7.73.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05).

Hedge Funds Weigh In On Sagimet Biosciences

A number of institutional investors have recently bought and sold shares of SGMT. China Universal Asset Management Co. Ltd. lifted its holdings in Sagimet Biosciences by 15.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,238 shares of the company’s stock worth $105,000 after purchasing an additional 1,500 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Sagimet Biosciences by 19.8% in the 2nd quarter. Baird Financial Group Inc. now owns 15,677 shares of the company’s stock valued at $121,000 after purchasing an additional 2,591 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Sagimet Biosciences in the 3rd quarter valued at $31,000. Fulcrum Asset Management LLP acquired a new position in Sagimet Biosciences in the 3rd quarter valued at $37,000. Finally, Profund Advisors LLC grew its holdings in Sagimet Biosciences by 36.1% in the 3rd quarter. Profund Advisors LLC now owns 19,737 shares of the company’s stock valued at $195,000 after buying an additional 5,234 shares in the last quarter. Institutional investors and hedge funds own 87.86% of the company’s stock.

Sagimet Biosciences News Summary

Here’s some of the latest news about SGMT:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $29 price target. A separate analyst roundup reports an average price target of $26.07, suggesting analysts see potential upside, though targets are not guarantees. Sagimet Biosciences stock average analyst price target
  • Negative Sentiment: HC Wainwright cut its EPS forecasts across Q4 2026 and fiscal 2026–2029. It now expects a larger Q4 loss of $0.36 per share, versus $0.27 previously, and lowered its 2026–2028 loss estimates. Its projected 2029 profit estimate also fell to $0.72 from $0.89. These revisions point to weaker near- and medium-term earnings expectations and could pressure the shares. HC Wainwright expects lower earnings for Sagimet Biosciences
  • Negative Sentiment: Canaccord Genuity Group trimmed its price target for SGMT, another potentially unfavorable analyst signal; the article listing does not specify the revised target. Canaccord Genuity Group trims Sagimet Biosciences price target

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Read More

Earnings History and Estimates for Sagimet Biosciences (NASDAQ:SGMT)

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.